Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRV045
- Development stage
- Phase 1
- Lead developer
- Trevena
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain, particularly diabetic peripheral neuropathy, and epilepsy. It demonstrates sustained analgesic effects without causing receptor desensitization or lymphopenia, unlike other S1P modulators like fingolimod. TRV045 is developed by Trevena, Inc.
02
Targets
EDG1 (Sphingosine-1-phosphate receptors)
Beyond the preview
Go deeper on TRV045.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRV045.